REFERENCES
1. Zundel KM. Telemedicine: history, applications, and impact on librarianship. Bull Med Libr Assoc 1996;84:71-9.
2. Freiburger G, Holcomb M, Piper D. The STARPAHC collection: part of an archive of the history of telemedicine. J Telemed Telecare 2007;13:221-3.
4. Raut CP, George S, Hornick JL, et al. High rates of histopathologic discordance in sarcoma with implications for clinical care. JCO 2011;29:10065.
5. Rupani A, Hallin M, Jones RL, Fisher C, Thway K. Diagnostic differences in expert second-opinion consultation cases at a tertiary sarcoma center. Sarcoma 2020;2020:9810170.
6. Tucker JH, Busch C, Spatz A, Wells C, Brugal G. An experimental inter-expert telepathology network using static imaging. J Clin Pathol 2001;54:752-7.
7. Voelker HU, Poetzl L, Strehl A, Mueller-Hermelink HK, Stuefe A, Stauch G. Telepathological evaluation of paediatric histological specimens in support of a hospital in Tanzania. Afr Health Sci 2020;20:1313-21.
8. Wamala D, Katamba A, Dworak O. Feasibility and diagnostic accuracy of Internet-based dynamic telepathology between Uganda and Germany. J Telemed Telecare 2011;17:222-5.
9. Racanelli D, Brenca M, Baldazzi D, et al. Next-generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC sarcoma working group. Front Oncol 2020;10:489.
10. Italiano A, Dinart D, Soubeyran I, Bellera C, Esperou H, Delmas C, et al. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. BMC Cancer 2021;21:1180.
11. Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol 2017;28:2852-9.
12. von Mehren M, Kane JM, Bui MM, et al. NCCN guidelines insights: soft tissue sarcoma, version 1.2021. J Natl Compr Canc Netw 2020;18:1604-12.
13. Siegel GW, Biermann JS, Chugh R, et al. The multidisciplinary management of bone and soft tissue sarcoma: an essential organizational framework. J Multidiscip Healthc 2015;8:109-15.
14. Rajasekaran RB, Whitwell D, Cosker TDA, Gibbons C, Carr A. Will virtual multidisciplinary team meetings become the norm for musculoskeletal oncology care following the COVID-19 pandemic? BMC Musculoskelet Disord 2021;22:18.
15. Bate J, Wingrove J, Donkin A, Taylor R, Whelan J. Patient perspectives on a national multidisciplinary team meeting for a rare cancer. Eur J Cancer Care 2019;28:e12971.
16. WHO classification of tumours editorial board. Soft tissue and bone tumours. International Agency for Research on Cancer: Lyon, France. 2020. Available from: https://publications.Iarc.fr/588 [Last accessed on 27 Sep 2022].
17. Smrke A, Younger E, Wilson R, et al. Telemedicine during the COVID-19 pandemic: impact on care for rare cancers. JCO Glob Oncol 2020;6:1046-51.
18. McCabe HM, Smrke A, Cowie F, et al. What matters to US: impact of telemedicine during the pandemic in the care of patients with sarcoma across scotland. JCO Glob Oncol 2021;7:1067-73.
19. Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients’ preferences for communication. J Clin Oncol 2001;19:2049-56.
20. Harris J, Cheevers K, Armes J. The emerging role of digital health in monitoring and supporting people living with cancer and the consequences of its treatments. Curr Opin Support Palliat Care 2018;12:268-75.
21. Denis F, Basch E, Septans AL, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA 2019;321:306-7.
22. Maguire R, McCann L, Kotronoulas G, et al. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ 2021;374:n1647.
23. Mooney KH, Beck SL, Wong B, et al. Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT. Cancer Med 2017;6:537-46.
24. Galizia D, Milani A, Geuna E, et al. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: a prospective study. Cancer Med 2018;7:4339-44.
25. Youn P, Milano MT, Constine LS, Travis LB. Long-term cause-specific mortality in survivors of adolescent and young adult bone and soft tissue sarcoma: a population-based study of 28,844 patients. Cancer 2014;120:2334-42.
26. Baker LH, Boonstra PS, Reinke DK, Antalis EJP, Zebrack BJ, Weinberg RL. Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study. J Cancer Metastasis Treat 2020;6:24.
27. Tonning Olsson I, Brinkman TM, Wang M, et al. Neurocognitive and psychosocial outcomes in adult survivors of childhood soft-tissue sarcoma: a report from the St. Jude Lifetime Cohort. Cancer 2020;126:1576-84.
28. Drabbe C, Van der Graaf WTA, De Rooij BH, et al. The age-related impact of surviving sarcoma on health-related quality of life: data from the SURVSARC study. ESMO Open 2021;6:100047.
29. Roberts AL, Fisher A, Smith L, Heinrich M, Potts HWW. Digital health behaviour change interventions targeting physical activity and diet in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 2017;11:704-19.
